Abstract BackgroundFinancial recession mandated the introduction of harsh austerity measures. Health, and particularly pharmaceuticals, constitute a significant part of public expenditure and as such they have been subject to significant budget reduction and stringent policies. As a consequence of these measures, an increasing percentage of patients resort to private sector for acquisition of their prescribed pharmaceuticals, due to exclusion of public health care beneficiary status, reduction of breadth of national formularies, delays in reimbursement and excessive waiting times. Affordability for pharmaceuticals in the private sector is of paramount importance since household disposable income plummets and more people are prone to impoverishment. This is critical for branded products, whose active substance and trademark are under patent protection, since no alternative options exist while their monopoly status imply that their prices are high. The impact on affordability regarding access of patient to necessary pharmaceutical care has not been documented in developed countries. MethodsA laspeyer index was constructed to compare prices of branded pharmaceuticals and assess affordability, by adjusting price index with Gross Domestic Product Purchase Power Parity per capita. Laspeyer index compares prices based on weights, which in our study are the corresponding sales of products in Cyprus. Moreover, we define the percentage of population that will face catastrophic pharmaceutical expenditure after acquisition of one product from eight major and common therapeutic categories. We used data from five European recession countries: Italy, Portugal, Spain, Greece and Cyprus, for 48 products which were selected based on sales. ResultsCyprus displays the highest prices for pharmaceuticals. By adjusting for Gross Domestic Product Purchase Power Parity per capita, affordability is worst for Cyprus and Portugal. ConclusionsAs more patients have to resort to private sector for provision of adequate and timely healthcare, health agencies must reassess affordability of medicines and minimise catastrophic expenditure impact. Health agencies should primarily try to enhance efficiency of the system and reduce waste, instead of resorting to blunt budget reduction, which can demonstrate unpredictable consequences in public health.
Cyprus              0.9999999993731308^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Cyprus                

pharmaceuticals               0.996577484044498^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Pharmaceutical_drug   

pharmaceuticals               0.996577484044498^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Pharmaceutical_drug   

private sector                1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Private_sector        

healthcare                    1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Health_care           

Gross Domestic Product        1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Gross_domestic_product

Italy                         0.9999896728946909^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Italy                 

public health                 0.9998130034467515^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Public_health         

formularies                   0.9999999999413376^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Formulary_(pharmacy)  

resort                        0.959507435285867^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Resort                

health                        0.9995444888479239^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Health_care           

Cyprus                        0.9999999993731308^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Cyprus                

European recession            1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Great_Recession_in_Europe

private sector                1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Private_sector        

Portugal                      0.9999066968059098^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Portugal              

Portugal                      0.9999066968059098^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Portugal              

public expenditure            0.9999974701456891^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Government_spending   

pharmaceutical care           0.9999997306936529^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Pharmaceutical_care   

pharmaceutical                0.9841242267228385^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Pharmaceutical_drug   

monopoly                      0.9999999999777174^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Monopoly              

austerity measures            1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Austerity             

recession                     0.9997944758960824^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Recession             

beneficiary                   0.9999990925573027^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Beneficiary           

disposable income             0.9999999999408828^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Disposable_and_discretionary_income

trademark                     0.9574880813033885^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Trademark             

Cyprus                        0.9999999993731308^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Cyprus                

private sector                1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Private_sector        

Gross Domestic Product        1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Gross_domestic_product

Greece                        0.9993738213126057^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Greece                

pharmaceuticals               0.996577484044498^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Pharmaceutical_drug   

pharmaceuticals               0.996577484044498^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Pharmaceutical_drug   

waste                         0.9999365428637746^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Pollution             

Spain                         0.9999624662518778^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Spain                 

developed countries           0.9776410322338394^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Developed_country     

pharmaceuticals               0.996577484044498^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Pharmaceutical_drug   

public health care            0.9999983507664141^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Universal_health_care 

resort                        0.959507435285867^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Resort                

patent                        0.9999999999158717^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Patent                

